Phase 2 Study of AT13387 (Onalespib) in ALK+ ALCL, MCL, and BCL-6+ DLBCL

NCT02572453 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

25

Enrollment

NIH

Sponsor class

Stopped Drug supply issues

Conditions

Recurrent Anaplastic Large Cell Lymphoma
Recurrent Diffuse Large B-Cell Lymphoma
Recurrent Mantle Cell Lymphoma
Recurrent Transformed Non-Hodgkin Lymphoma
Refractory Anaplastic Large Cell Lymphoma
Refractory Diffuse Large B-Cell Lymphoma
Refractory Mantle Cell Lymphoma
Refractory Transformed Non-Hodgkin Lymphoma

Interventions

DRUG: Onalespib

Sponsor

National Cancer Institute (NCI)